Abstract

SALINAS-LEZAMA, Erika et al. Nephrological effects of SGLT2. What do we know so far?. Med. interna Méx. [online]. 2019, vol.35, n.3, pp.379-388.  Epub Mar 05, 2021. ISSN 0186-4866.  https://doi.org/10.24245/mim.v35i3.2443.

Prevalence of type 2 diabetes has increased significantly. It is inferred that the number of adults with diabetic nephropathy will also increase. Therefore, diabetic nephropathy will gain importance in global health and there is a need to minimize morbidity associated to this disease. Sodium-glucose transporter type 2 (SGLT2) inhibitors are the latest pharmacologic class of oral antidiabetics. They act upon the inhibition of SGLT2 co-transporters located in the luminal membrane of cells in the proximal convoluted tubule. Significant reductions in glycated haemoglobin levels, along with lower fasting glucose levels have been associated to SGLT2 inhibitors. Efficacy of SGLT2 inhibitors is affected with kidney failure, nonetheless, a subgroup study showed that SGLT2 inhibitors administered in the context of kidney failure (KDIGO stage 3b or 4) have neutral effects over HbA1C levels, but positive effects over other biochemical parameters and weight loss. The objective of this article is to review literature of renal effects of SGLT2 inhibitors.

Keywords : Type 2 diabetes; Diabetic nephropathy; Antidiabetics; Sodium-glucose transporter 2 inhibitors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )